Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

bioAffinity Technologies (BIAF) Invested Capital (2022 - 2025)

Historic Invested Capital for bioAffinity Technologies (BIAF) over the last 4 years, with Q3 2025 value amounting to $9.0 million.

  • bioAffinity Technologies' Invested Capital rose 12281.27% to $9.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.0 million, marking a year-over-year increase of 12281.27%. This contributed to the annual value of $3.4 million for FY2024, which is 4316.91% down from last year.
  • bioAffinity Technologies' Invested Capital amounted to $9.0 million in Q3 2025, which was up 12281.27% from -$2.0 million recorded in Q2 2025.
  • bioAffinity Technologies' 5-year Invested Capital high stood at $22.0 million for Q3 2022, and its period low was -$2.0 million during Q2 2025.
  • For the 4-year period, bioAffinity Technologies' Invested Capital averaged around $7.2 million, with its median value being $6.4 million (2024).
  • The largest annual percentage gain for bioAffinity Technologies' Invested Capital in the last 5 years was 12281.27% (2025), contrasted with its biggest fall of 14382.38% (2025).
  • bioAffinity Technologies' Invested Capital (Quarter) stood at $11.3 million in 2022, then plummeted by 46.38% to $6.1 million in 2023, then crashed by 43.17% to $3.4 million in 2024, then skyrocketed by 162.3% to $9.0 million in 2025.
  • Its Invested Capital stands at $9.0 million for Q3 2025, versus -$2.0 million for Q2 2025 and $2.2 million for Q1 2025.